NBHL joins a press conference for the new Collaborative Drug Discovery Ecosystem Initiative

— Enhancing GPCR Antibody Pipeline Value Through AI Integration —

NB Health Laboratory Co., Ltd. (Head Office: Sapporo, Hokkaido, Japan; President : Kiyoshi Takayama) participated as an initial partner company in a press conference hosted by FRONTEO, Inc. on February 12, 2026. The event, titled “New Collaborative Drug Discovery Ecosystem Initiative to Strengthen Japan’s Drug Discovery Capabilities,” was held at JP Tower Hall & Conference (Marunouchi, Tokyo) and was conducted in a hybrid format, including simultaneous Zoom streaming.

The announcement was also covered by major external media, including:

The Nikkei (Japan’s leading financial newspaper)
https://www.nikkei.com/article/DGXZQOSG123MK0S6A210C2000000/

Nippon Television News (video coverage via Yahoo! Japan)
https://news.yahoo.co.jp/articles/ea695b7a380c988b7adc10194f4ba0af242b021f

At the event, FRONTEO introduced its new initiative, “DDAIF Innovation Bridge,” centered on its AI-powered platform, Drug Discovery AI Factory (DDAIF). The initiative combines AI-driven hypothesis generation for Drug Discovery, causal inference analysis, and strategic support with the aim of improving R&D efficiency and increasing the probability of successful out-licensing among Japanese biotech companies.

During the partner company session, President Takayama presented the Company’s GPCR antibody drug discovery platform, “MoGRAA®,” and shared the results of a proof-of-concept (PoC) study conducted using DDAIF. The PoC indicated the potential of AI-driven, hypothesis-based discovery to identify novel target–disease relationships and to contribute to the enhancement of pipeline value.

NBHL is advancing GPCR-targeted antibody therapeutics as a core growth strategy. Through this collaboration, the Company aims to achieve non-linear enhancement of pipeline value and to generate mid- to long-term revenue opportunities.
The Company will continue to integrate AI technologies to maximize the probability of success in drug discovery and remains committed to the creation of innovative antibody therapeutics originating from Japan, with the objective of achieving global out-licensing.